Skip to content

Tumour markers response to chemotherapy in patients with colorectal liver metastases

Molecular Biomarkers for Colorectal Liver Metastases Resectability after Chemotherapy with Cetuximab - POCHER-2

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2012-000834-21-IT
Enrollment
Unknown
Registered
2012-04-03
Start date
2012-04-01
Completion date
Unknown
Last updated
2012-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PATIENTS WITH LIVER COLORECTAL METASTASES NOT CANDIDATED TO SURGERY MedDRA version: 14.1 Level: LLT Classification code 10024700 Term: Liver metastases System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Interventions

Trade Name: ERBITUX*INFUS 1FL 50ML 5MG/ML Pharmaceutical Form: Powder and solvent for solution for infusion INN or Proposed INN: CETUXIMAB CAS Number: 205923-56-4 Concentration unit: mg/ml milligram(s

Sponsors

ISTITUTI FISIOTERAPICI OSPITALIERI
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: COLORECTAL LIVER METASTASES UNRESECTABLE ACCORDING TO NORTLINGER CLASSIFCIATION (ANN.ONCOL.2009) Are the trial subjects under 18? no Number of subjects for this age range: 0 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 270 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 30

Exclusion criteria

Exclusion criteria: EXTENSION OF DISEASE OUTSIDE THE LIVER

Design outcomes

Primary

MeasureTime frame
Main Objective: COMPLETE LIVER RESECTION AFTER CHEMOTHERAPY;Secondary Objective: TIME TO SURGERY TIME TO PROGRESSION TOLERABILITY RESPONSE RATE OVERALL SURVIVAL;Primary end point(s): COMPLETE RESECTION OF LIVER METASTASES;Timepoint(s) of evaluation of this end point: 4 MONTHS

Secondary

MeasureTime frame
Secondary end point(s): TIME TO PROGRESSION;Timepoint(s) of evaluation of this end point: 24 MONTHS

Countries

Italy

Contacts

Public ContactONCOLOGIA MEDICA A

ISTITUTO REGINA ELENA

garufi@ifo.it06-52666919

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026